Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BAX 855 (PEGylated Recombinant Factor VIII): A Phase 1, Prospective, Open Label, Cross-Over, Dose-Escalation Study in Previously Treated Patients (PTPs) With Severe (FVIII < 1%) Hemophilia A

Trial Profile

BAX 855 (PEGylated Recombinant Factor VIII): A Phase 1, Prospective, Open Label, Cross-Over, Dose-Escalation Study in Previously Treated Patients (PTPs) With Severe (FVIII < 1%) Hemophilia A

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 26 Oct 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rurioctocog alfa pegol (Primary) ; Octocog alfa
  • Indications Haemophilia A
  • Focus Adverse reactions
  • Sponsors Baxter Healthcare Corporation
  • Most Recent Events

    • 06 Dec 2016 Results assessing Immunogenicity of Rurioctocog-alfa-pegol using patient data (n=243) from this and other six trials (NCT02585960, NCT02210091, NCT01736475, NCT01913405, NCT01945593, NCT02615691) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 16 Jul 2015 According to a Baxalta media release, data from this study was published in Blood, the journal of American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top